Stock Scorecard
Stock Summary for INmune Bio Inc (INMB) - $7.40 as of 3/31/2025 4:15:56 PM EST
Total Score
7 out of 30
Safety Score
25 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for INMB
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for INMB
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for INMB
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for INMB
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for INMB (25 out of 100)
| Stock Price Rating (Max of 10) | 4 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 5 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for INMB
Financial Details for INMB
Company Overview |
|
|---|---|
| Ticker | INMB |
| Company Name | INmune Bio Inc |
| Country | USA |
| Description | INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease, and nonalcoholic steatohepatitis. The company is headquartered in La Jolla, California. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 9/30/2024 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 7.40 |
| Price 4 Years Ago | 10.20 |
| Last Day Price Updated | 3/31/2025 4:15:56 PM EST |
| Last Day Volume | 342,490 |
| Average Daily Volume | 263,587 |
| 52-Week High | 12.72 |
| 52-Week Low | 4.32 |
| Last Price to 52 Week Low | 71.30% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 53.93 |
| Sector PE | 40.10 |
| 5-Year Average PE | -7.24 |
| Free Cash Flow Ratio | 5.00 |
| Industry Free Cash Flow Ratio | 18.14 |
| Sector Free Cash Flow Ratio | 47.05 |
| Current Ratio Most Recent Quarter | 2.59 |
| Total Cash Per Share | 1.48 |
| Book Value Per Share Most Recent Quarter | 1.74 |
| Price to Book Ratio | 4.54 |
| Industry Price to Book Ratio | 11.03 |
| Sector Price to Book Ratio | 21.92 |
| Price to Sales Ratio Twelve Trailing Months | 4,786.99 |
| Industry Price to Sales Ratio Twelve Trailing Months | 59.91 |
| Sector Price to Sales Ratio Twelve Trailing Months | 27.78 |
| Analyst Buy Ratings | 2 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 22,692,200 |
| Market Capitalization | 167,922,280 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -9.92% |
| Reported EPS 12 Trailing Months | -1.90 |
| Reported EPS Past Year | -1.71 |
| Reported EPS Prior Year | -1.67 |
| Net Income Twelve Trailing Months | -41,272,000 |
| Net Income Past Year | -30,008,000 |
| Net Income Prior Year | -27,299,000 |
| Quarterly Revenue Growth YOY | -63.20% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | -98,921.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 33,552,000 |
| Total Cash Past Year | 35,848,000 |
| Total Cash Prior Year | 52,153,000 |
| Net Cash Position Most Recent Quarter | 31,058,000 |
| Net Cash Position Past Year | 20,927,000 |
| Long Term Debt Past Year | 14,921,000 |
| Long Term Debt Prior Year | 15,000,000 |
| Total Debt Most Recent Quarter | 2,494,000 |
| Equity to Debt Ratio Past Year | 0.71 |
| Equity to Debt Ratio Most Recent Quarter | 0.94 |
| Total Stockholder Equity Past Year | 37,340,000 |
| Total Stockholder Equity Prior Year | 60,104,000 |
| Total Stockholder Equity Most Recent Quarter | 38,675,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -25,749,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.13 |
| Free Cash Flow Past Year | 0 |
| Free Cash Flow Prior Year | 0 |
Options |
|
| Put/Call Ratio | 0.44 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.07 |
| MACD Signal | -0.04 |
| 20-Day Bollinger Lower Band | 3.09 |
| 20-Day Bollinger Middle Band | 6.82 |
| 20-Day Bollinger Upper Band | 10.56 |
| Beta | 1.94 |
| RSI | 44.74 |
| 50-Day SMA | 7.42 |
| 150-Day SMA | 8.25 |
| 200-Day SMA | 9.65 |
System |
|
| Modified | 3/27/2025 11:25:36 PM EST |